REGULATORY

Japan Panels Agree to Add Myocarditis as ADRs for Pfizer, Moderna Vaccines

December 6, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Panels of experts under the Japanese health ministry on December 3 agreed on label revisions for mRNA COVID-19 vaccines developed by Pfizer and Moderna to add myocarditis and pericarditis to their list of clinically significant adverse drug reactions (ADRs). The…

To read the full story

No Major Safety Concerns for COVID-19 Jabs: MHLW Panels
January 24, 2022
Second Case of TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
December 27, 2021
TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
November 15, 2021
MHLW Panels Continue to See No Major Safety Concerns for COVID-19 Jabs
October 25, 2021
No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW Panels
October 4, 2021
Tainted Moderna Jabs Run Afoul of PMD Law: Minister
September 16, 2021
Causal Link between Deaths and Recalled Batch of Moderna Jab “Indeterminable”
September 13, 2021
Systemic Symptoms Unlikely to Occur from Contaminated Moderna Jabs: Japan Vaccinology Society
September 9, 2021
Post-Vaccination Death Cases Being Investigated with Integrity: Takeda
September 8, 2021
Takeda Recalling Suspended Batches of Moderna Jabs in Japan; Administrative Action Possible
September 2, 2021
No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
August 6, 2021
Label Revisions Ordered for AstraZeneca’s COVID-19 Vaccine; Thrombocytopenia Added to Adverse Reactions
July 28, 2021
Panels Agree to Add Risk of Thrombocytopenia to AstraZeneca Vaccine Label
July 27, 2021
No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
July 9, 2021
No Major Concerns over Safety of Moderna, Pfizer COVID-19 Vaccines: MHLW
June 11, 2021
MHLW Panels to Analyze Group-Based Data for Post-COVID-19 Vaccination Deaths
May 27, 2021
No Serious Safety Concerns Detected for Comirnaty: MHLW Safety Panels
May 14, 2021
Don’t Take Vaccines If You Feel Ill: Safety Panels to Elderly
April 26, 2021
COVID-19 Vaccine Reactions More Common in Women, Younger People: MHLW Study
April 12, 2021
Vaccine Safety Panels to Evaluate Suspected Anaphylaxis Cases Based on Pfizer’s Reports
April 12, 2021
35.6% of Pfizer Vaccine Recipients Developed Fevers after 2nd Shot, Higher Incidence in Women: MHLW
March 29, 2021
No Significant Concerns Observed with Pfizer COVID-19 Vaccine: Japan Safety Panels
March 15, 2021
Site Pain Common with COVID-19 Vaccine, but It Improves in 3 Days: Safety Follow-Up
March 15, 2021
Japan Confirms 1st Case of Anaphylaxis from COVID-19 Vaccination
March 8, 2021
Woman Dies 3 Days after COVID-19 Vaccine Shot, but Link Indeterminable
March 3, 2021

REGULATORY

Voranigo and More Meds Missing from April Listing Slate; Servier Plans Packaging Change
April 10, 2026
Health Insurance Reform Bill Enters Diet Debate; OTC-Like Drug Charges in Focus
April 10, 2026
CEPI Seeks Continued Technology, Funding Ties with Japan
April 10, 2026
Dialysis Tubing and Medical Device Makers Fret over Long-Term Supply Risks
April 10, 2026
Japan Moves to Bypass Wholesalers in Fuel Supply to Hospitals
April 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…